1:43 PM
 | 
Aug 03, 2018
 |  BioCentury  |  Finance

Karuna’s CNS double play

How Karuna plans to deploy $42M A round to revive xanomeline’s development

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies.

Along with founding investor PureTech Health PLC (LSE:PRTC), the round included Arch Venture Partners, the Wellcome Trust and Karuna Chairman Steven Paul, as well as undisclosed other backers.

Karuna believes its KarXT xanomeline/trospium chloride may be able to replicate the efficacy signals seen in trials of xanomeline alone to treat schizophrenia and Alzheimer’s disease, while avoiding gastrointestinal and other side effects that compelled Eli Lilly and Co. (NYSE:LLY) to scuttle xanomeline’s development long ago.

“Karuna’s approach is simple but elegant.”

Steven Paul, Karuna

Paul, a longtime Lilly employee and the lead...

Read the full 598 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >